Telemedicine and the “Zoom effect” boost big-cap medtech
In the second half of 2020 medtech began a tentative – and possibly short-lived – recovery.
Covid-19 divides the biggest medtechs
Success or failure on the stock markets this year depended almost entirely on whether a company’s devices could be used to treat coronavirus patients.
2019 was all about execution for smaller device makers
New products and strategic execution buoyed mid and small-cap medtechs, while safety worries took down one former high-flier.
Big cap medtech comes roaring back
Exact Sciences finds that where there’s muck there’s brass, but specialisation does not work as well for Abiomed.
The fourth quarter sell-off hurt big medtech less than big pharma
Some medtech stocks did decline in 2018, but many more increased in value.
Smaller medtechs soar in ’17 but could now be too expensive
Many small groups are up thanks to takeover speculation, and this may end up being self-defeating.
